H.C. Wainwright analyst Ram Selvaraju has reiterated their bullish stance on CRVO stock, giving a Buy rating on November 5.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Ram Selvaraju has given his Buy rating due to a combination of factors related to CervoMed’s promising drug candidate, neflamapimod. The company has received positive feedback from the FDA, allowing it to move forward with a pivotal Phase 3 clinical trial for the treatment of dementia with Lewy bodies (DLB), a condition with no currently approved treatments in the U.S. or EU. This trial is designed to be rigorous, excluding patients with Alzheimer’s disease co-pathology and focusing on a clear primary endpoint of global cognition and function.
Additionally, despite reporting a higher net loss than expected for the third quarter of 2025, primarily due to increased R&D spending, CervoMed’s financial position remains strong with $27.3 million in cash and equivalents. The company is expected to require additional capital to advance neflamapimod to regulatory submission, but some of this could be sourced through non-dilutive means such as partnerships. These strategic advancements and financial plans underpin Selvaraju’s confidence in the stock’s potential, supporting the Buy rating with a 12-month price target of $25.
Selvaraju covers the Healthcare sector, focusing on stocks such as Emergent Biosolutions, Bioxcel Therapeutics, and Vanda. According to TipRanks, Selvaraju has an average return of 23.3% and a 51.40% success rate on recommended stocks.
In another report released on November 5, Roth MKM also reiterated a Buy rating on the stock with a $20.00 price target.